DBP International AB: The sterilization of SI-053 has been validated - five out of ten milestones for the clinical trial of SI-053 have been completed
Double Bond Pharmaceutical International AB (publ) (“DBP”) reports that the sterilization of SI-053 has been validated and completed. The process was carried out by a company specializing in sterilization services located in the EU, in close collaboration with a contracted partner that manufactures SI-053 for the upcoming Phase 1 clinical trial. "This is an important part of the product development, which means that we will provide patients with a sterile and safe product, according to EU requirements" - comments Igor Lokot, CEO of DBP. 10 communicated